SciClone Pharmaceuticals was founded in 1989 and is headquartered in Foster City, US

SciClone Pharmaceuticals has an office in Foster City

Foster City, US (HQ)

900 950 Tower Ln

SciClone Pharmaceuticals's revenue was reported to be $42.9 m in Q1, 2017

USD

## Revenue (Q1, 2017) | 42.9 m |

## Gross profit (Q1, 2017) | 36.7 m |

## Gross profit margin (Q1, 2017), % | 86% |

## Net income (Q1, 2017) | 14.6 m |

## EBIT (Q1, 2017) | 14.2 m |

## Market capitalization (18-Aug-2017) | 591.1 m |

## Cash (31-Mar-2017) | 141.3 m |

SciClone Pharmaceuticals's current market capitalization is $591.1 m.

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 127.1 m | 134.8 m | 157.3 m | 160.1 m |

## Revenue growth, % | 6% | 17% | 2% | |

## Cost of goods sold | 22.3 m | 22.9 m | ||

## Gross profit | 134.9 m | 137.2 m | ||

## Gross profit Margin, % | 86% | 86% | ||

## Operating expense total | 127.3 m | 126.9 m | ||

## EBIT | 10.4 m | 26 m | 29.9 m | 33.2 m |

## EBIT margin, % | 8% | 19% | 19% | 21% |

## Net Income | 11 m | 25.2 m | 29.5 m | 30.7 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 32.5 m | 34.3 m | 33.6 m | 37.9 m | 42.9 m | 36.5 m | 39 m | 40.5 m | 42.9 m |

## Cost of goods sold | 5 m | 6 m | 4.6 m | 5.7 m | 6.9 m | 5.8 m | 5.7 m | 5.6 m | 6.2 m |

## Gross profit | 27.5 m | 28.3 m | 29 m | 32.3 m | 36 m | 30.7 m | 33.3 m | 35 m | 36.7 m |

## Gross profit Margin, % | 85% | 82% | 86% | 85% | 84% | 84% | 85% | 86% | 86% |

## Sales and marketing expense | 11.2 m | 13.9 m | 11.1 m | 13 m | 15.1 m | 12.4 m | 14.4 m | 13.3 m | 12.8 m |

## R&D expense | 804 k | 653 k | 1.1 m | 6.6 m | 1 m | 1.5 m | 4.8 m | 3.3 m | 2.5 m |

## General and administrative expense | 5.8 m | 5.6 m | 7.3 m | 6.8 m | 7.3 m | 7.4 m | 8.1 m | 7.9 m | 7.2 m |

## Operating expense total | 17.9 m | 20.2 m | 19.5 m | 26.3 m | 23.4 m | 21.3 m | 27.3 m | 24.5 m | 22.5 m |

## EBIT | 9.6 m | 8.1 m | 9.5 m | (4.9 m) | 12.6 m | 9.4 m | 6 m | 10.5 m | 14.2 m |

## EBIT margin, % | 30% | 24% | 28% | (13%) | 29% | 26% | 15% | 26% | 33% |

## Net Income | 9.6 m | 7.9 m | 9 m | (4 m) | 12 m | 7.9 m | 6.3 m | 10.1 m | 14.6 m |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 85.8 m | 86.2 m | 101.4 m | 134.4 m |

## Accounts Receivable | 40.3 m | |||

## Inventories | 15.2 m | 10.7 m | 11 m | 16.6 m |

## Current Assets | 143.4 m | 140.2 m | 168.5 m | 195.7 m |

## PP&E | 843 k | 1.8 m | 2.7 m | 2 m |

## Goodwill | 35.4 m | 34.5 m | 33 m | 30.8 m |

## Total Assets | 180.2 m | 181.8 m | 216.6 m | 241.9 m |

## Accounts Payable | 7.2 m | 5.3 m | 4.5 m | 3.6 m |

## Current Liabilities | 33.6 m | 26.4 m | 36.8 m | 26.4 m |

## Additional Paid-in Capital | 278.3 m | 287.1 m | 296.1 m | 304.6 m |

## Retained Earnings | (136 m) | (135.1 m) | (118.5 m) | (87.8 m) |

## Total Equity | 146.6 m | 155.3 m | 179.7 m | 215.4 m |

## Financial Leverage | 1.2 x | 1.2 x | 1.2 x | 1.1 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 87 m | 96.8 m | 96 m | 93 m | 99.2 m | 114.7 m | 117.6 m | 130.1 m | 141.3 m |

## Accounts Receivable | 32.4 m | ||||||||

## Inventories | 16.3 m | 14.2 m | 8.9 m | 12 m | 12.1 m | 12.2 m | 11.3 m | 13.8 m | 15.3 m |

## Current Assets | 141.3 m | 146.7 m | 140.1 m | 146.4 m | 153.8 m | 162.2 m | 167.7 m | 184.2 m | 207.1 m |

## PP&E | 1.2 m | 1.6 m | 2.5 m | 2.5 m | 2.2 m | 2.4 m | 2.1 m | 1.8 m | 1.8 m |

## Goodwill | 34.5 m | 34.9 m | 34.5 m | 34.5 m | 33.7 m | 33.2 m | 32.3 m | 32.1 m | 31.1 m |

## Total Assets | 177.5 m | 186.2 m | 182.3 m | 195.9 m | 202.2 m | 210.4 m | 214.5 m | 233.4 m | 253.5 m |

## Accounts Payable | 6.6 m | 6.4 m | 2.4 m | 5.4 m | 3.8 m | 3.3 m | 2.6 m | 4.7 m | 2 m |

## Current Liabilities | 23.3 m | 26 m | 18.8 m | 35.2 m | 36.2 m | 20.8 m | 21.4 m | 24.6 m | 20 m |

## Additional Paid-in Capital | 281.4 m | 285.2 m | 289 m | 292.7 m | 294.3 m | 297.8 m | 295.8 m | 301.4 m | 307.8 m |

## Retained Earnings | (130.8 m) | (128.8 m) | (128.9 m) | (135.5 m) | (131 m) | (110.6 m) | (104.3 m) | (94.2 m) | (73.3 m) |

## Total Equity | 154.1 m | 160.2 m | 163.4 m | 160.6 m | 166 m | 189.5 m | 193 m | 208.7 m | 233.4 m |

## Financial Leverage | 1.2 x | 1.2 x | 1.1 x | 1.2 x | 1.2 x | 1.1 x | 1.1 x | 1.1 x | 1.1 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | 11 m | 25.2 m | 29.5 m | 30.7 m |

## Depreciation and Amortization | 860 k | 852 k | 931 k | 985 k |

## Accounts Receivable | (4.2 m) | (3.3 m) | 306 k | (2.4 m) |

## Inventories | (4.7 m) | 5.9 m | 1.4 m | (3 m) |

## Accounts Payable | (652 k) | (5.5 m) | (2.3 m) | (3.1 m) |

## Cash From Operating Activities | 9.5 m | 27.6 m | 32.5 m | 34.5 m |

## Purchases of PP&E | (324 k) | (1.5 m) | (1.8 m) | (648 k) |

## Cash From Investing Activities | 55 k | (6.2 m) | (9 m) | (3.4 m) |

## Cash From Financing Activities | (8.4 m) | (20.8 m) | (8.4 m) | 1.9 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | 9.6 m | 7.9 m | 9 m | (4 m) | 12 m | 7.9 m | 6.3 m | 10.1 m | 14.6 m |

## Accounts Receivable | 32.4 m | ||||||||

## Inventories | 16.3 m | 14.2 m | 8.9 m | 12 m | 12.1 m | 12.2 m | 11.3 m | 13.8 m | 15.3 m |

## Accounts Payable | 6.6 m | 6.4 m | 2.4 m | 5.4 m | 3.8 m | 3.3 m | 2.6 m | 4.7 m | 2 m |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 75.2 k |

## Financial Leverage | 1.1 x |